Mulberroside A: A Comprehensive Reference
1. Identity and Chemical Characterization
1.1 Names and Classification
Mulberroside A is a stilbenoid found in Morus alba, the white mulberry, and is specifically the diglucoside of oxyresveratrol. It is a natural polyhydroxylated stilbene compound present at relatively high abundance in the roots and twigs of Morus alba L. The compound is classified within the broader stilbenoid (hydroxystilbene) family of polyphenols, structurally distinguished from its aglycone, oxyresveratrol, by the attachment of two glucose moieties.
According to PubChem (CID 6443484), the molecular formula of Mulberroside A is C26H32O14. Its systematic IUPAC name, as characterized by spectroscopic analysis, describes the compound as a bis-glucopyranoside in which two β-d-glucopyranose units are O-linked to the oxyresveratrol scaffold at the 3 and 4′ positions. The compound carries the CAS registry number 102841-42-9, and its geometric isomer cis-mulberroside A is assigned CAS 166734-06-1.
Mulberroside A is a glycosylated stilbenoid with potential use in pharmacology and chemical analysis, owing to its distinctive structural and chemical properties. It serves as a reference compound in phytochemical fingerprinting, especially for the quality monitoring of herbal medicines sourced from mulberry species, with analytical methods such as HPLC and UV-spectrophotometry used to evaluate its concentration as an indicator of authenticity and quality.
1.2 Botanical Source and Plant Distribution
Mulberry (Morus alba L.) belongs to the Moraceae family and is widely planted in Asia. It is native to China and has been widely cultivated in many regions including Asia, Africa, America, Europe, and India. China has planted mulberry for more than 5,000 years.
Mulberroside A is found at relatively high abundance in the roots and twigs of Morus alba L. It has also been isolated from the root bark of Morus alba L. (Moraceae), along with its geometric isomer cis-mulberroside A and oxyresveratrol. Additionally, mulberroside A has been identified among nine stilbenes isolated from the aerial parts of Veratrum maackii Regel, a plant used in traditional Chinese medicine, demonstrating that this compound is not exclusive to the genus Morus.
Quantitative analysis of Ramulus Mori (mulberry twig) ethanol extract by HPLC has found mulberroside A to be the principal constituent, at approximately 14.9 mg/g of dried extract, substantially exceeding the levels of oxyresveratrol (4.8 mg/g) and resveratrol (0.24 mg/g).
1.3 Common Forms and Preparations
Morus alba L. is a common traditional Chinese medicine with a centuries-old medicinal history, with various medicinal parts including Mori folium (leaf), Mori ramulus (twig), Mori cortex (root bark), and Mori fructus (fruit). Mulberroside A is concentrated most significantly in the twig (Mori ramulus) and root bark (Mori cortex) fractions. Among the phenylpropanoids present in Morus alba, trans-oxyresveratrol and mulberroside A are particularly noted in the reference literature for their association with antioxidant, anti-inflammatory, and neuroprotective properties.
In commercial and research contexts, mulberroside A is obtained either by isolation from mulberry plant material or as a standardized constituent of standardized mulberry extracts. Skin-lightening properties have been demonstrated by crude extracts or isolated phenolic compounds from root barks, twigs, and leaves of the plant; isolated compounds of interest include oxyresveratrol and its mono- and di-glycosylated (mulberroside A) forms, as well as moracin M, kaempferol, quercetin, rutin, resveratrol, and morin. Topically, mulberroside A has been incorporated into cosmeceutical preparations such as creams, lotions, and serums targeting skin hyperpigmentation.
2. Traditional and Historical Use
2.1 Traditional Chinese Medicine (TCM)
All parts of the mulberry plant, including roots, leaves, twigs, and fruits, have been used as traditional Chinese medicines for thousands of years and are recorded in the Compendium of Materia Medica (Bencao Gangmu), the famous Chinese encyclopedia of medicine written by Shizhen Li in the Ming dynasty. Historically, all parts of the mulberry tree have been used to address a spectrum of physiological conditions, including cooling, sedation, diuresis, tonicity, and neuropathy; its leaves in particular have been employed as sweat inducers, cooling agents, and antipyretic agents, in addition to their nutritional value.
Mulberry twig is a commonly used traditional Chinese medicine. The ancient medical book The Newly Revise Materia Medica records that mulberry twig "has a clear and bitter taste, slightly cold, non-toxic, and enters the liver meridian," while the Suixiju Diet Spectrum records that mulberry twig can "nourish the liver and kidney, enrich blood."
Known as Sangzhi in Chinese, Ramulus Mori (the dried mulberry twig) is widely used in traditional Chinese medicine to treat gout, arthritis, and rheumatism. Mulberroside A is a major stilbene glycoside of Morus alba L. (Moraceae) that is effectively used for the treatment of hyperuricemia and gout in traditional Chinese medicine. According to traditional Chinese medicine, mulberry fruits are also used to improve eyesight and protect against liver damage. Mulberry has been used in traditional Oriental medicine to treat diabetes and premature white hair.
The leaves of the white mulberry (Morus alba) have been used in traditional Chinese medicine (TCM) for a long time. The leaves of Morus alba L. have a long history in Traditional Chinese Medicine and became valued by the ethnopharmacology of many other cultures; the worldwide known antidiabetic use of the drug has been suggested to arise from a complex combination effect of various constituents.
2.2 Other Traditional Systems
Mulberries (Morus sp.) are traditionally utilized as a nutritional food providing health benefits as well as skin nourishment in Thailand. Across the broader Asian subcontinent, one of the most cultivated species of mulberry tree, Morus alba, has attracted increasing focus from researchers because of its abundance in phytochemicals as well as its multipurpose uses. Mulberry paper, produced from the plant's bark fiber, was a preferred material for traditional Chinese painting paper in ancient times.
3. Key Constituents, Related Compounds, and Mechanisms of Action
3.1 Structural Context: Oxyresveratrol and the Stilbene Scaffold
Mulberroside A's pharmacological activity must be understood in the context of its metabolic relationship with oxyresveratrol (OXY), its aglycone. Mulberroside A is a natural polyhydroxylated stilbene compound known for its nephroprotective, hypoglycemic, and antidiabetic effects; its metabolite oxyresveratrol possesses purported anti-inflammatory and neuroprotective effects, leading researchers to propose that mulberroside A itself may elicit neuroprotective actions.
When incubated anaerobically with intestinal bacteria, mulberroside A undergoes rapid deglycosylation and generates two monoglucosides and its aglycone oxyresveratrol sequentially. In humans, mulberroside A is rapidly deglycosylated by intestinal bacteria to provide two monoglucosides and oxyresveratrol sequentially; oxyresveratrol is then quickly absorbed and undergoes hepatic conjugation to provide oxyresveratrol 2-O-β-d-glucuronide and oxyresveratrol sulfate. A further study using human liver and intestinal microsomes revealed that 2-O-β-d-glucuronide is the major metabolite, and UDP-glucuronosyltransferases (UGTs) are the enzymes involved in the transformation.
3.2 Co-occurring Active Compounds in Morus alba
Phytochemistry studies have indicated that Morus alba mainly contains flavonoids, polyphenols, anthocyanins, terpenes, carotenoids, and alkaloid-type metabolites, such as kuwanon G, morusin, and 1-deoxynojirimycin. Chemical constituents of Mori ramulus include flavonoids, benzofurans, alkaloids, stilbenes, chalcones, phenolic acids, and coumarins; bioactivities include antidiabetic, anti-obesity, anti-inflammatory, antityrosinase, neuroprotective, antioxidant, hepatoprotective, renoprotective, antihyperuricemic, analgesic, and antiplatelet aggregation properties. The most active compounds from Ramulus Mori are considered to be mulberrin, oxyresveratrol, and mulberroside A.
3.3 Principal Mechanisms of Action
Tyrosinase and Melanogenesis Inhibition: Tyrosinase is the rate-limiting enzyme in melanogenesis, catalyzing the oxidation of tyrosine to 3,4-dihydroxy-l-phenylalanine and subsequently to dopaquinone; inhibiting tyrosinase is thus a key strategy for preventing skin hyperpigmentation. For monophenolase activity, the inhibitory activity of mulberroside A was reversible and showed mixed type 1 inhibition, with KI values of 0.385 µmol/L and KIS values of 0.177 µmol/L; for diphenolase activity, mulberroside A showed competitive inhibition with a KI of 4.36 µmol/L. It can therefore be concluded that mulberroside A inhibits the production of melanin by inhibiting the activity of tyrosinase.
Anti-inflammatory Signaling: Mechanistic studies showed that mulberroside A decreased the expressions of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), and inhibited the activation of NALP3 inflammasome components. In hepatoprotective studies, the expressions of the Keap1–Nrf2 signal pathway, the nuclear factor-kappa B (NF-κB) signal pathway, and the mitogen-activated protein kinase (MAPK) signal pathway-related proteins have been evaluated in relation to mulberroside A treatment. Mulberroside A has been demonstrated to markedly inhibit pro-inflammatory cytokine release in liver tissues and in cultured macrophages, thereby alleviating liver fibrosis.
Urate Transport Modulation: Mulberroside A downregulated mRNA and protein levels of renal glucose transporter 9 (mGLUT9) and urate transporter 1 (mURAT1), which are responsible for urate reabsorption in the kidney. The compound was also reported to upregulate mRNA and protein levels of renal organic anion transporter 1 (mOAT1) and carnitine transporters (mOCT1, mOCT2, mOCTN1, and mOCTN2), indicating its potential as an antihyperuricemic and nephroprotective agent.
NF-κB and P-glycoprotein Pathway: The NF-κB signaling pathway plays a crucial role in mulberroside A-induced suppression of P-glycoprotein (P-gp).
Metabolic Pathways In Vivo: A total of 72 metabolites of mulberroside A have been identified in rat systems, with metabolic pathways mainly comprising hydrolysis, glucuronidation, hydrogenation, sulfation, hydroxylation, methylation, and composite reactions. The metabolic result showed that the main forms of mulberroside A in vivo were the glucuronidation and sulfation products of its aglycone, while in vitro they were mainly the hydroxylation and hydrolysis products of its prototype.
4. Scientific Evidence by Area of Use
4.1 Skin Hyperpigmentation and Melanogenesis Inhibition
Evidence level: Preclinical (in vitro and animal); limited human cosmetic data.
Many stilbene glycosides can alleviate skin hyperpigmentation due to their inhibitory effect on tyrosinase. Mulberrosides in Morus alba L. are stilbene glycosides; in a study investigating the inhibition of tyrosinase by five isolated mulberrosides, these compounds exhibited obvious inhibitory effects in a concentration-dependent manner without time-dependence, indicating they are reversible inhibitors. Among the five compounds tested, certain mulberrosides inhibited tyrosinase activity with IC50 values more potent than kojic acid (IC50 = 169.13 µM), and kinetic studies revealed that different mulberrosides acted as competitive or mixed inhibitors.
Chromatographic analysis of a white mulberry fruit extract confirmed it contained rutin, chlorogenic acid, and mulberroside A — compounds known to possess strong antioxidant and anti-tyrosinase activities. Mulberroside A is unique to mulberries and has demonstrated efficacy in reducing melanogenesis.
A study involving the topical application of oxyresveratrol, mulberroside A, and oxyresveratrol-3-O-glucoside to brown-skinned guinea pigs found that all three successfully inhibited tyrosinase activity and significantly reduced melanin content in the skin of animals exposed to UV rays, causing depigmentation. Of the three compounds, oxyresveratrol exhibited the highest anti-melanogenesis effect and mulberroside A the lowest, though both were effective; the study suggested these compounds have potential as skin-whitening agents.
Dedicated human clinical trials examining mulberroside A alone for skin lightening have not been identified in the peer-reviewed literature. Existing evidence for skin applications remains at the in vitro and animal level, and any cosmeceutical applications draw primarily from preclinical data.
4.2 Hyperuricemia and Gout (Antihyperuricemic and Nephroprotective Effects)
Evidence level: Animal (murine models); no published human clinical trials identified for mulberroside A specifically.
Mulberroside A is a major stilbene glycoside of Morus alba L. (Moraceae), used for the treatment of hyperuricemia and gout in traditional Chinese medicine; researchers investigated whether it had effects on renal urate underexcretion and dysfunction in oxonate-induced hyperuricemic mice. Mulberroside A at doses of 10, 20, and 40 mg/kg decreased serum uric acid levels and increased urinary urate excretion and fractional excretion of uric acid in hyperuricemic mice. Simultaneously, it reduced serum levels of creatinine and urea nitrogen (at 10–40 mg/kg), urinary N-acetyl-β-d-glucosaminidase activity, β₂-microglobulin, and albumin, and increased creatinine clearance. This study was described as the first demonstrating that mulberroside A exhibits uricosuric and nephroprotective effects mediated in part by cooperative attenuation of the expression alterations of renal organic ion transporters in hyperuricemic mice.
Mulberroside A, as a resveratrol derivative, has been shown to exhibit uricosuric and nephroprotective properties in potassium oxonate-treated mice, downregulating the expression of urate reabsorption transporters (URAT1, GLUT9) and increasing that of excretion transporters such as OAT1. Ramulus Mori is commonly used to treat gout and hyperuricemia in traditional Chinese medicine prescriptions, though exact mechanisms of its efficacy remained unclear until studies demonstrated that its ethanol extract exerted uricosuric and nephroprotective effects in hyperuricemic mice.
4.3 Neuroprotection and Ischemic Injury
Evidence level: Preclinical (in vitro, cell culture, and animal models); no human clinical trials identified.
Mulberroside A is known for its nephroprotective, hypoglycemic, and antidiabetic effects; because its metabolite oxyresveratrol possessed purported anti-inflammatory and neuroprotective effects, researchers investigated the pharmacological properties of mulberroside A in primary culture of rat cortical neurons after oxygen-glucose deprivation followed by reperfusion (OGD/R) to evaluate its ability to counteract hypoxia-ischemia impairment. The results showed that mulberroside A elicited neuroprotective effects comparable to nimodipine, and mechanistic studies showed that it decreased the expressions of TNF-α, IL-1β, and IL-6 and inhibited the activation of NALP3 inflammasome signaling. Proinflammatory cytokines IL-1β, IL-6, and TNF-α were confirmed as promising targets for treatment of cerebral ischemic injury; all findings led the authors to speculate that mulberroside A is a candidate for the treatment of ischemic stroke as a multifactorial neuroprotectant.
A separate study demonstrated that mulberroside A was capable of preventing high-fructose diet-induced damage to the intestinal epithelial barrier and blood-brain barrier in mice, which may contribute to the suppression of hippocampal neuroinflammatory injury.
4.4 Hepatoprotective Effects (Liver Protection)
Evidence level: Animal (rodent models); no human clinical trials identified for mulberroside A alone.
Contemporary pharmacological studies have shown that mulberry twigs have anti-inflammatory and antioxidant biological activities; however, systematic investigation on the hepatoprotective effect of its main active ingredient mulberroside A (MulA) was previously lacking, prompting researchers to explore its role in CCl₄-induced liver injury. MulA treatment significantly alleviated CCl₄-induced liver injury as evidenced by histological analysis and Masson staining; MulA inhibited the expressions of collagen I and α-SMA in livers of CCl₄-treated mice but did not directly inhibit the proliferation and activation of hepatic stellate cells. Importantly, it markedly inhibited pro-inflammatory cytokine release in liver tissues and in cultured macrophages, thereby alleviating liver fibrosis, leading researchers to suggest MulA as a potential therapeutic candidate for liver injury and inflammatory diseases.
A separate study comparing the hepatoprotective effects of oxyresveratrol, resveratrol, and mulberroside A at 80 mg/kg body weight per day (administered intragastrically) on acute liver injury induced by lipopolysaccharide/d-galactosamine in mice found that treatment with all three compounds could significantly decrease levels of alanine transaminase (ALT) and aspartate transaminase (AST), key markers of liver damage.
4.5 Anti-inflammatory and Analgesic Effects
Evidence level: Preclinical (in vitro and animal); no human clinical trials identified.
The mulberroside class of compounds has been found to have anti-inflammatory, anti-hyperlipidemic, antioxidant, antiviral, anticancer, liver-protective, lung-protective and antitussive, bone-protective, uric acid-lowering, hypoglycemic, neuroprotective, and other properties. Pharmacological studies have documented hypoglycemic (Li et al., 2014), antidiabetic (Xu et al., 2021), anti-inflammatory (Chung et al., 2003), analgesic (Zhang and Shi, 2010), hepatic protective (Zhang et al., 2008), nephroprotective (Wang et al., 2011), melanogenesis-inhibiting (Park et al., 2011), and neuroprotective (Wang et al., 2014) effects of mulberroside A.
Intervertebral disc degeneration (IVDD) is a common spine disease with inflammation as its main pathogenesis; mulberroside A possesses anti-inflammatory characteristics in many diseases, and its therapeutic potential on IVDD has been explored in vitro and in vivo using IL-1β-induced nucleus pulposus cells and puncture-induced IVDD rat models. Mulberroside A has been reported to alleviate osteoarthritis via restoring impaired autophagy and suppressing MAPK/NF-κB/PI3K-AKT-mTOR signaling pathways.
4.6 Hypoglycemic and Antidiabetic Effects
Evidence level: Preclinical (animal and cell models); clinical evidence pertains primarily to mulberry-derived preparations and alkaloids, not mulberroside A in isolation.
In recent years, the mulberry plant has attracted extra attention in the context of modern research particularly with regard to the regulation of blood sugar levels and metabolic health; this scientific interest has led to intensified use of white mulberry as a functional food or dietary supplement. Mulberroside A has been cited among the compounds contributing to hypoglycemic activity. Studies have shown that mulberroside A has antitussive, antiasthmatic, tyrosinase-inhibiting, and antioxidation activities.
Clinical research on Ramulus Mori alkaloids (SZ-A) in a multicenter, randomized controlled trial found that these mulberry twig-derived compounds exhibited hypoglycemic effects similar to acarbose and were accompanied by a lower incidence of treatment-related adverse events and gastrointestinal disorders in patients with type 2 diabetes mellitus. However, it should be noted that this clinical evidence applies to the alkaloid fraction (specifically 1-deoxynojirimycin and related iminosugars) rather than to mulberroside A itself, which remains primarily studied at the preclinical level for glucose-lowering effects.
4.7 Antitussive and Antiasthmatic Effects
Evidence level: Animal studies only.
Mulberroside A, a major stilbene constituent of Morus alba L. (Moraceae), displays significant antitussive and antiasthmatic effects in animals. Oral administration studies in rats have characterized its metabolic fate in the gastrointestinal tract, with the biotransformation products in rats identified as oxyresveratrol-2-O-β-d-glucopyranoside, oxyresveratrol-3′-O-β-d-glucopyranoside, and oxyresveratrol, detected in both small intestinal contents and feces.
5. Body Systems and Health Areas Associated with Mulberroside A
- Integumentary system (skin): The antioxidant and tyrosinase-inhibiting effects of mulberroside A show promise for skin whitening and anti-aging applications.
- Renal system: Data suggest that mulberroside A may be a new drug candidate for the treatment of hyperuricemia with renal dysfunction.
- Hepatic system: Mulberroside A, identified as the main active ingredient from mulberry twig, was found to significantly alleviate CClâ‚„-induced liver injury as evidenced by histological analysis.
- Nervous system: Findings have led researchers to speculate that mulberroside A is a candidate for the treatment of ischemic stroke, where it would act as a multifactorial neuroprotectant.
- Musculoskeletal system: Mulberroside A possesses anti-inflammatory characteristics with relevance to diseases of the joints and intervertebral discs.
- Metabolic system: Pharmacological studies have documented hypoglycemic and antidiabetic effects of mulberroside A, among a range of other activities.
- Respiratory system: Studies have shown that mulberroside A has antitussive and antiasthmatic activities.
6. Pharmacokinetics and Bioavailability
6.1 Oral Bioavailability
A pharmacokinetic study on mulberroside A revealed that its oral absolute bioavailability was poor in rats. When Mori Cortex extracts were administered orally, mulberroside A was only detected in small quantities in the plasma, and its bioavailability was approximately 1%; this is attributed to a first-pass effect by which most mulberroside A was converted into oxyresveratrol.
Mulberroside A exhibited poor permeability and predominantly traversed Caco-2 cells via passive diffusion; in contrast, the permeation of oxyresveratrol across Caco-2 cells was much more rapid and involved efflux mediated by both P-glycoprotein and multidrug resistance-associated proteins (MRPs). Oxyresveratrol underwent extensive hepatic glucuronidation, while the parent mulberroside A was kept intact in liver subcellular preparations. There was insignificant species difference in intestinal bacterial conversion of mulberroside A between humans and rats.
6.2 Metabolism and Metabolites
The in vivo and in vitro metabolites of mulberroside A were mostly derived from its hydrolyzed products oxyresveratrol-4-O-β-d-glucopyranoside or oxyresveratrol-3′-O-β-d-glucopyranoside and oxyresveratrol. The main metabolic reactions were hydrolysis, hydroxylation, methylation, sulfation, glucuronidation, and their compound reactions. The main forms of mulberroside A in vivo were the glucuronidation and sulfation products of its aglycone, while in vitro they were mainly the hydroxylation and hydrolysis products of its prototype. An in vitro pharmacokinetic study showed that the glucose group on mulberroside A was rapidly hydrolyzed to generate monoglycosides and oxyresveratrol when incubated anaerobically with intestinal bacteria.
The rapid metabolism of mulberroside A results in low absorption and bioavailability, and subsequent studies need to improve the bioavailability via appropriate routes of administration or pharmaceutical preparations.
7. Dosage Forms and Reported Study Dosages
No established standardized clinical dosage for mulberroside A as an isolated supplement has been identified in the peer-reviewed literature. The following dosages appear specifically in preclinical or research contexts and are reported here solely as stated in those sources:
- In an oxonate-induced hyperuricemia mouse model, mulberroside A was administered at 10, 20, and 40 mg/kg body weight, producing dose-dependent decreases in serum uric acid levels and increases in urinary urate excretion.
- A hepatoprotective comparison study used mulberroside A at 80 mg/kg body weight per day by intragastric administration in an LPS/d-galactosamine-induced acute liver injury mouse model.
- For metabolic characterization studies, mulberroside A was administered intragastrically to rats at a dose of 150 mg/kg.
Because of its low bioavailability and rapid metabolism, pharmacokinetic data for mulberroside A remain unsatisfactory, and subsequent studies need to improve its bioavailability via appropriate routes of administration or pharmaceutical preparations to provide references for clinical applications.
In cosmeceutical topical applications, mulberroside A is incorporated as part of mulberry extract formulations. No specific topical concentration for isolated mulberroside A has been identified; however, a 3% cream of a 70% ethanolic extract of white mulberry leaves has been developed and evaluated for stability, physicochemical properties, and preservative effectiveness under accelerated conditions for skin hyperpigmentation applications.
8. Safety Considerations and Drug Interactions
8.1 P-glycoprotein-Mediated Herb-Drug Interactions
Mulberroside A treatment could down-regulate P-glycoprotein (P-gp) expression and function, accompanied by the activation of PKC and NF-κB, and this should be taken into consideration in potential herb-drug interactions when mulberroside A or Morus alba are co-administered with other drugs transported by P-gp. P-glycoprotein is a major efflux transporter governing the intestinal absorption and tissue distribution of many drugs, and modulation of P-gp activity by phytochemicals can meaningfully alter the pharmacokinetics of co-administered P-gp substrate drugs.
8.2 Bioavailability and First-Pass Considerations
Mulberroside A exhibited poor permeability across intestinal cells and was predominantly converted to oxyresveratrol by intestinal bacteria before systemic absorption. A study of the effect of piperine on the pharmacokinetic profile of oral oxyresveratrol found that the oral availability of oxyresveratrol was enhanced twofold when given in combination with piperine. This finding has indirect relevance to mulberroside A given its rapid conversion to oxyresveratrol in the gut.
8.3 Traditional Safety Profile
The ancient Chinese medical book The Newly Revise Materia Medica records that mulberry twig is "non-toxic." The pharmacological activities of Morus alba, including anti-diabetic, anti-oxidative, anti-bacterial, anti-inflammatory, anti-atherogenic, and immunological enhancement properties, have been verified by modern experimental technologies. No significant toxicity findings specific to isolated mulberroside A have been reported in the peer-reviewed literature reviewed here; however, the absence of formal clinical toxicology studies for the isolated compound means that the human safety profile is incompletely characterized.
8.4 Antiasthmatic and Antitussive Context
In traditional Chinese medicine, Mori ramulus — the dried twigs of Morus alba L. — is extensively used as an antirheumatic agent and also finds additional use in asthma therapy. As pathological high xanthine oxidase (XO) activity is strongly correlated with hyperuricemia and gout, and because standard antihyperuricemic therapy with XO inhibitors like allopurinol can cause adverse effects by inhibiting other enzymes in purine metabolism, Mori ramulus may be a promising source for the development of new antirheumatic therapeutics with fewer side effects.
9. Current Research Status and Limitations
The research base for mulberroside A, while growing, is almost entirely preclinical. Mulberroside demonstrates diverse pharmacological properties with significant therapeutic potential across multiple body systems; however, the rapid metabolism of mulberroside results in low absorption and bioavailability, and subsequent studies need to improve bioavailability via appropriate routes of administration or pharmaceutical preparations to provide references for clinical applications.
The compound exhibits antiviral, antibacterial, and anticancer activities, offering new approaches for treating infections and cancer; additionally, lipid-regulating and anti-obesity effects may help prevent cardiovascular diseases. All of these claims remain at the preclinical investigation stage as of the current literature. The in vivo and in vitro metabolism of mulberroside A has been poorly understood historically, though newer analytical strategies employing UHPLC-Orbitrap mass spectrometry and network pharmacology are beginning to characterize its metabolic profile more thoroughly.
The compound's role as a prodrug-like precursor to the more bioavailable oxyresveratrol remains an important conceptual framework for interpreting its pharmacological effects: many activities ascribed to mulberroside A in vivo may be mediated primarily or partly through its metabolite. Established human clinical trials specifically using isolated mulberroside A for any indication have not been identified in the literature reviewed. Evidence for all areas of potential activity should be considered preliminary and largely confined to cell-based and animal studies.
References
Go back